Introduction {#s1}
============

The mammalian brain has evolved through multiple transitions between gyrencephaly and lissencephaly ([@bib33]). Cortical expansion and gyrification have been implicated in the evolution of human cognition; and dysplastic gyrification is associated with numerous neurodevelopmental disorders including hydrocephalus ([@bib26]; [@bib19]; [@bib18]; [@bib46]; [@bib4]). Yet, despite the high significance, the mechanisms which create a smooth or folded brain remain poorly understood.

*In vivo* mouse and ferret studies together with in vitro human organotypic slice analyses have identified several genetic, cell biological and biomechanical factors that contribute to gyrification ([@bib4]; [@bib36]). Stereotypic, *bona fide* cortical folding includes formation of gyri (away from ventricle) and sulci (proximal to ventricle) of differential thickness (gyri thicker than the sulci), adjacent to a predominantly unfolded apical ventricular lining ([@bib4]). Naturally gyrencephalic species undergo a sequence of developmental events referred to here as the 'gyrification sequence'. It begins with apical progenitor proliferation followed by differential expansion of secondary progenitors, comprising of intermediate precursors (IPs) and basal radial glia cells (bRGs). The expansion of progenitors is associated with focal modes of neuronal differentiation, and migration that is mediated by variable ECM stiffness ([@bib4]; [@bib36]). Although differential progenitor expansion is central to gyrification, little is known about the initiating steps of this highly regulated process ([@bib18]).

We previously generated mice with activating mutations of *Pik3ca*, the catalytic subunit of the phosphoinositide 3-kinase (PI3K) enzyme, to model human brain overgrowth syndromes including megalencephaly and epilepsy ([@bib52]). Since dysplastic cortical folding and developmental hydrocephalus are within the spectrum of PI3K-related brain overgrowth syndromes ([@bib40]; [@bib28]; [@bib24]), we have now used our tet-inducible activating *Pik3ca^H1047R^* mutant mice ([@bib52]) to study mechanisms underlying these additional phenotypes. Hydrocephalus, affecting approximately 1 in 1000 births, is among the most common neurodevelopmental disorders with often devastating outcome ([@bib19]; [@bib57]). It is characterized by abnormal expansion of brain ventricles (ventriculomegaly) and progressive accumulation of cerebrospinal fluid ([@bib26]; [@bib19]). New therapeutic approaches are urgently needed since current treatment requires invasive surgeries with associated significant complications ([@bib29]). PIK3CA-related hydrocephalus is a subtype of developmental hydrocephalus, caused by disrupted brain development associated with genetic abnormalities ([@bib58]; [@bib57]). Infantile hydrocephalus can also result from environmental insult, including intra-ventricular hemorrhage associated with prematurity ([@bib1]; [@bib25]). Despite identification of several contributing factors, the underlying cellular and molecular mechanisms that cause hydrocephalus remain largely unknown.

Here we report that Pik3ca activation in embryonic cortical progenitors during a critical two-day period was sufficient to drive cortical gyrification in mice. PI3K activation disrupted apical junctions and caused ectopic subcellular translocation of Yap leading to neural proliferation and gyrification, as well as abnormal ependymal development and hydrocephalus. Both the gyrification and hydrocephalus phenotypes were attenuated in the mutant mice by treatment with verteporfin ([@bib59]; [@bib53]; [@bib35]), a nuclear Yap inhibitor.

These results demonstrate that the PI3K/Hippo-Yap pathway is finely tuned to regulate cell adhesion and proliferation along the apical lining of the forebrain to maintain the lissencephalic mouse brain. Subtle alterations in this pathway during the mid-neurogenic phase have dramatic consequences for the cytoarchitecture of forebrain ventricular linings and the interrelated processes of neurogenesis, gyrification and ependymal development.

Results {#s2}
=======

*Pik3ca* activating mutations caused gyrification of the normally lissencephalic mouse cortex {#s2-1}
---------------------------------------------------------------------------------------------

We identified striking gyrification of the hippocampus and neocortex in the embryonically induced *GFAP-cre;Pik3ca^H1047R^* mutant mice ([Figure 1a--l](#fig1){ref-type="fig"}; [@bib52]) This mutant also recapitulates human PI3K-related developmental hydrocephalus, without any evidence of stenosis along the antero-posterior extent of the brain. In this model, a transgene encoding an activating *H1047R* mutation in the human *PIK3CA* gene has dual spatio-temporal regulation, such that the presence of both *cre* protein and doxycycline is required to activate the mutation in cre-positive neuronal progenitors ([Figure 1---figure supplement 1a,b](#fig1s1){ref-type="fig"}) ([@bib52]). The *GFAP-cre* driver used in this study gets activated in neural progenitors at around embryonic day (E)13 ([@bib62]; [@bib52]). Around this early activation time, this *cre* line demonstrates a strong high-medial-low-lateral expression gradient in the forebrain, as well as an apical-low-basal-high gradient within the lateral neocortex, as seen at E14.5 ([Figure 1---figure supplement 1c](#fig1s1){ref-type="fig"}). These differential gradients decrease gradually with the progression of developmental age ([Figure 1---figure supplement 1d](#fig1s1){ref-type="fig"}). Embryonically induced postnatal (P)3 *GFAP-cre;Pik3ca^H1047R^* mutants (doxycycline: E0.5\>P3) demonstrated highly convoluted medial tissue, with indistinct hippocampal morphology ([Figure 1b,d,f](#fig1){ref-type="fig"}) ([@bib52]). This hippocampal folding phenotype was 100% penetrant with stereotypic gyral pattern in all mutants (n \> 50) studied. 3-D models of P3 control and mutant hippocampi clearly demonstrate the differential anatomical features ([Video 1](#video1){ref-type="video"}, [Video 2](#video2){ref-type="video"}; still images in [Figure 1e,f](#fig1){ref-type="fig"}). Ventriculomegaly, indicating developing hydrocephalus, was also clearly evident in all of the mutant brains, seen from as early as E14.5 ([Figure 1b,d](#fig1){ref-type="fig"}; [Figure 1---figure supplement 2f,p--s](#fig1s2){ref-type="fig"}; [Figure 1---figure supplement 3a,c,e](#fig1s3){ref-type="fig"}). Less pronounced lateral neocortical folding was also evident with 100% penetrance, although variable in position ([Figure 1b,d](#fig1){ref-type="fig"}; [Figure 1---figure supplement 2f--i](#fig1s2){ref-type="fig"}). Both neocortical and hippocampal folds in the *Pik3ca^H1047R^* mutant mice followed the criteria of *bona fide* cortical gyrification ([@bib4]): a) folded pial surface and underlying layers, b) predominantly smooth apical surfaces adjacent to the lateral ventricle, c) differential thickness between gyri and sulci ([Figure 1---figure supplement 2f--i,p--s](#fig1s2){ref-type="fig"}). Notably, similar lateral and medial cortical gyrification was also documented in mice with *Pik3ca^H1047R^* mutation activated by *Emx1-cre* ([@bib9]). Together, these data demonstrate that Pik3ca activation is sufficient to cause cortical gyrification across the entire mouse dorsal telencephalon with the phenotype likely dependent on the time and regional gradients of *cre* activity, and regional differences in neurogenic periods.

![Embryonic induction of *Pik3ca^H1047R^* activating mutation causes cortical gyrification in mice.\
(**a--d**) Nissl-stained coronal sections of P3 control and *GFAP-cre;Pik3ca^H1047R^* mutant hemi-forebrains revealed hippocampal (dotted lines) and neocortical gyrification (open arrowheads), when induced embryonically. (**e,f**) 3D models of control and mutant hippocampi. (**g--l**) Gross patterning of all hippocampal substructures was intact, as shown by Ctip2, Satb2 and Tbr1 expression. Medial gyrification was restricted primarily to the mutant CA1 region. CA -- cornus ammonis (red dotted line, **a--d**); sub -- subiculum; DG -- dentate gyrus (blue dotted line, a-d; **g--j**). Scale bars: 1 mm (**a--d**), 100 μm (**n--s**). See also [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"}--[3](#fig1s3){ref-type="fig"}.](elife-45961-fig1){#fig1}

###### 3D model of P3 control hippocampus.

10.7554/eLife.45961.006

###### 3D model of P3 *GFAP-cre;Pik3ca^H1047R^* hippocampus.

10.7554/eLife.45961.007

Focal increases in progenitors initiated *bona fide* cortical gyrification in *Pik3ca^H1047R^* mutant {#s2-2}
-----------------------------------------------------------------------------------------------------

To determine if *Pik3ca^H1047R^* mice modeled *bona fide* cortical gyrification seen in naturally gyrified mammals ([@bib4]), we assessed neural patterning and progenitor proliferation during embryogenesis. We focused on the developing hippocampus, where gyrification was most prominent in pattern and location. P3 *Pik3ca^H1047R^* mutants showed normally patterned subdivisions of hippocampus proper (CA1-4) and dentate gyrus (DG; [Figure 1g--l](#fig1){ref-type="fig"}). Similar to the control littermates, Ctip2 expression was high in the mutant CA1 and DG, sparse in CA2 and absent in Tbr1^+^ CA3. Ctip2 expression also revealed that the gyrification in mutants was primarily restricted to CA1, with possibly secondary folding evident in the DG. The *Pik3ca* activating mutation resulted in a significant increase in the lengths of P3 CA field (p\<0.0001) and dentate gyrus (p=0.03), compared to the respective controls ([Figure 1---figure supplement 3a,b](#fig1s3){ref-type="fig"}). The first visual sign of reproducible cortical folding was observed at E16.5 in the *Pik3ca^H1047R^* mutant dorso-lateral neocortex ([Figure 1---figure supplement 3e](#fig1s3){ref-type="fig"}).

Further histological analyses confirmed that *GFAP-cre;Pik3ca^H1047R^* mutants replicated the coordinated neurogenic sequence seen in gyrencephalic mammals. Compared with control, both E14.5 and E16.5 mutants had significantly longer medial ventricular linings (p=0.0028 and p\<0.0001 respectively; [Figure 1---figure supplement 3c--f](#fig1s3){ref-type="fig"}), suggesting early expansion of apical progenitors. Short BrdU pulse confirmed significantly higher proliferation (p\<0.05) in mutants at E14,5, but not at E16.5, compared to respective controls ([Figure 2b--e](#fig2){ref-type="fig"}). Sox2^+^ primary progenitors in the mutant CA1 ventricular-subventricular zone were significantly increased at E14.5 (p\<0.05) and decreased at E16.5 (p\<0.01). Tbr2^+^ IPs) were unchanged at E14.5; but significantly increased at E16.5 (p\<0.05), demonstrating a gradual increase in secondary progenitor pool *in lieu* of the primary progenitors ([Figure 2f--i](#fig2){ref-type="fig"}). This trend of higher progenitor number was maintained even postnatally, especially in the mutant gyral ventricular-subventricular zone ([Figure 2l--m'](#fig2){ref-type="fig"}). The number of Sox2^+^Tbr2^-^ bRGs in outer subventricular zone was not significantly different between control and mutant at E16.5 ([Figure 2i](#fig2){ref-type="fig"}). The mutant CA1 further demonstrated significantly higher neuronal differentiation at E16.5 ([Figure 2j,k](#fig2){ref-type="fig"}).

![Altered neurogenesis in *Pik3ca^H1047R^* mutant at embryonic and postnatal stages follows the stereotypic cortical 'gyrification sequence'.\
(**a**) Schematics of E14.5 and E16.5 coronal hemi-section, boxes represent region of interest (**b,d,f,h,j**). Images are oriented with lateral neocortex on the top, followed by lateral ventricle (LV) and then CA1 (**b,d,f,h,j,l--o'**). (**b--e**) Compared to control, E14.5 *Pik3ca^H1047R^* mutants exhibited significantly higher labeling index, indicating higher proliferation rate. Though E16.5 mutant CA1 showed no overt change in labeling index, pHH3^+^ cells marking the M-phase appeared to be ectopic (yellow arrowheads), indicating early mis-localization of dividing cells. (**f--i**) Compared with respective controls, E14.5 and E16.5 *GFAP-cre;Pik3ca^H1047R^* mutants, induced from E0.5, showed significant increase in primary (apical Sox2^+^Tbr2^-^, aRGs) and secondary (Tbr2^+^ IPs; basal Sox2^+^Tbr2^-^, bRGs) progenitor pools, in accordance with the gyrification sequence; yellow circle marks bRG. Data are normalized and represented as mean ± SEM in scatter plots; 2-tailed unpaired t-tests were performed (**c,e,g,i**). (**j,k**) Cell cycle exit during the E15.5-E16.5 period was significantly higher in the mutant CA1 than the control, as represented in mean ± SEM scatter plots (t = 10.16, degrees of freedom (df) = 21.73). (**l--m'**) Compared to controls, P3 mutant CA1 region showed focal increase in Pax6^+^ and Tbr2^+^ progenitors at the gyral ventricular-subventricular zone; the apical edge remained predominantly unfolded. (**n--o'**) Nestin^+^ and GFAP^+^ intermediate filaments in P3 were misoriented and divergent from focal points (asterisks) at the mutant gyri. (**p**) Schematics of P3 control and mutant hemi-sections; boxes depict regions shown in l-o'. Differences were considered significant at p\<0.05; ns, not significant. nctx, neocortex; PL, pyramidal layer. Scale bars: 50 μm (**b,d,f,h,j**), 100 μm (**l--o'**). See also [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}.](elife-45961-fig2){#fig2}

Birth-dating analysis showed normal neuronal fate specification in P0 mutant CA1 ([Figure 2---figure supplement 1a--c](#fig2s1){ref-type="fig"}). Although the mutant hippocampal subdivisions were grossly intact, there were minor migration defects as evidenced by a loosely packed *stratum pyramidale* (PL), reduced *stratum lacunosum-moleculare* (*slm*), and scattered Calbindin^+^ pyramidal cell subtype in the gyral white matter ([Figure 2l',m'](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1f--i,k,l](#fig2s1){ref-type="fig"}). Similar to our report of the neocortical phenotype ([@bib52]), we observed a disrupted Nestin^+^/GFAP^+^ radial glial scaffold throughout mouse embryogenesis, starting as early as E14.5 ([Figure 2---figure supplement 1d--i](#fig2s1){ref-type="fig"}). A divergent fiber distribution was evident postnatally at each gyrus, similar to that seen in naturally gyrencephalic species ([Figure 2n--o'](#fig2){ref-type="fig"}) ([@bib13]; [@bib4]). Focally concentrated progenitor cells found in the P3 gyral ventricular-subventricular zone and the funneling effect of radial glial scaffold fibers most certainly amplified the earlier developmental disruptions leading to *bona fide* gyrification of the normally lissencephalic cortex.

*Pik3ca* mutation-driven gyrification in mice had a short embryonic critical period {#s2-3}
-----------------------------------------------------------------------------------

Although numerous mouse models of cortical gyrification exist, our highly regulatable model is an extremely valuable tool to dissect fundamental molecular mechanisms. Specifically, via temporally restricted doxycycline administration, we generated a time-series of *GFAP-cre;Pik3ca^H1047R^* mutants to begin to dissect mechanisms underlying gyrification and other phenotypes ([Figure 3b--d,f--i](#fig3){ref-type="fig"}). Consistent with our previous study ([@bib52]), postnatal induction of *Pik3ca^H1047R^* allele failed to cause overtly abnormal brain morphology ([Figure 3i](#fig3){ref-type="fig"}). By contrast, doxycycline induction from either E0.5 or E13.5 generated the most severely gyrified CA1 with identical stereotypic pattern ([Figure 3b--d,k](#fig3){ref-type="fig"}). This was not unexpected since despite doxycycline availability, the *cre* protein was produced in neural progenitors only from \~E13 ([@bib52]). Pik3ca-related ventriculomegaly resulted broadly from mutation induction at any embryonic time point ([Figure 1b,d](#fig1){ref-type="fig"}; [Figure 1---figure supplement 2f,p](#fig1s2){ref-type="fig"}; [Figure 1---figure supplement 3a,c,e](#fig1s3){ref-type="fig"}; [Figure 3b--d,f--h](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1c](#fig3s1){ref-type="fig"}).

![Non-random gyrification pattern in *Pik3ca^H1047R^* mutant has a narrow embryonic critical period.\
(**a--j**) Nissl-stained coronal hemi-sections depicting hippocampal morphology, alongside schematics (**e,j**). Compared to control (**a**), *Pik3ca^H1047R^* mutant hippocampus showed graded severity in gyrification, depending on the time and duration of mutation induction. The critical period of the most severe folding with a non-random folding pattern ends at E15.5 (**b--d**). Postnatal induction of *Pik3ca^H1047R^* mutation is not effective to cause cortical gyrification (**i**). (**k**) Developmental timeline of mutation induction and the corresponding hippocampal gyrification phenotype. Scale bars: 1 mm (**a--d, f--i**). See also [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.](elife-45961-fig3){#fig3}

Remarkably, a short 2 day window of doxycycline administration from E13.5 to (\>) E15.5 was sufficient to completely recapitulate the highly stereotypic gyrification pattern seen in mutants with constitutive administration of doxycycline throughout development. Despite the identical gyrification pattern, the CA1 PL of P3 (doxycycline: E13.5 \> E15.5) mutant was more compact than that of the constitutively activated mutants, suggesting a later role for activated Pik3ca in regulating the minor neuronal migration abnormalities detected in this model. Shorter periods of doxycycline treatment (E13.5 \> E14.5, E14.5 \> E15.5) within this critical period did not result in gyrification, despite mild cortical dysplasia and ventriculomegaly ([Figure 3---figure supplement 1b--e](#fig3s1){ref-type="fig"}). Induction beyond E15.5 (E15.5 \> P3, E15.5 \> E17.5, E17.5 \> P0) caused a gradual attenuation of the gyrification phenotype and significantly smaller CA1 PL lengths in the respective P3 mutants ([Figure 3f--h,k](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1a](#fig3s1){ref-type="fig"}). To further define gyrification mechanisms, we therefore focused our analysis of developmental events using minimally induced (doxycycline E13.5 \> E15.5) mutant mice.

Disordered junctional proteins at embryonic ventricular lining were the earliest presage of the mutant gyrification phenotype {#s2-4}
-----------------------------------------------------------------------------------------------------------------------------

The first obvious morphological sign of CA1 gyrification in minimally induced (doxycycline E13.5 \> E15.5) mutants was a medial 'ripple' at E17.5 ([Figure 3---figure supplement 1f--n](#fig3s1){ref-type="fig"}). This was accompanied by dispersed radial glial fibers, loosely packed Ctip2^+^ PL with ectopic Calbindin^+^ cells, as well as reduced *slm* marked by cell adhesion molecule L1 ([Figure 3---figure supplement 1o--v](#fig3s1){ref-type="fig"}). Since these phenotypes suggested that neuronal migration abnormalities might underlie the gyrification phenotype, we investigated localization of ECM protein Reelin in the *Pik3ca^H1047R^* mutant. Reelin is well-known for its role in cell migration; and its expression in Cajal-Retzius cells is typically required to direct normal lamination of pyramidal neurons in the development of CA fields ([@bib8]). Further, ectopic Reelin has been reported to contribute to cortical dysplasia in another mouse model of PI3K pathway overactivation ([@bib2]). However, we found no evidence of ectopic Reelin^+^ cells in either E17.5 or P2 mutant CA1 regions ([Figure 2---figure supplement 1m,n](#fig2s1){ref-type="fig"}; [Figure 3---figure supplement 1r,v](#fig3s1){ref-type="fig"}).

Focal increases in proliferation observed at the mutant ventricular-subventricular zone suggested that disruptions at the apical (ventricular) linings were fundamental to the gyrification phenotype. In control E16.5 and P3 mice, the neocortical and hippocampal ventricular linings are tightly juxtaposed ([Figure 4b--e](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1b--d](#fig4s1){ref-type="fig"}). The normal juxtaposition of apical membranes was disrupted in E16.5 mutants, leading to the formation of loose gaps/bubbles along the edge ([Figure 4f--i](#fig4){ref-type="fig"}), which eventually resulted in completely unzippered ventricular linings postnatally ([Figure 4---figure supplement 1e--j](#fig4s1){ref-type="fig"}). Junctional proteins delineating the ventricular surface, including β−Catenin, N-Cadherin, ZO-1 ([@bib27]), were focally discontinuous and often ectopic in P3 mutants, compared to their littermate controls. Milder, yet clear disruptions of cell polarity were observed at E16.5 and E14.5 along the mutant medial apical membrane ([Figure 4f--i,o--r](#fig4){ref-type="fig"}).

![Embryonic induction of *Pik3ca^H1047R^* mutation causes early disruption of apical cell adhesion.\
(**a,j**) Schematic of E14.5 and E16.5 hemi-section showing area of interest. (**b--i**) Compared to control, E16.5 *Pik3ca^H1047R^* mutant, induced from E0.5, showed abnormal zippering of forebrain apical membranes (open arrowheads, (**f--h**), with XZ plane indicating subtle mis-localization of cell adhesion molecules β-Catenin and ZO-1 (**d,h**). N-Cadherin, that is normally expressed uniformly at the juxtaposition of the apical membranes (**e**), appeared to be clustered around the unzippered portion and sporadically absent (asterisk) in adjacent parts of the membrane junction (**i**). (**k--r**) Compared to control, CA1 ventricular lining of E14.5 mutant showed subtle disruption in the localization of β-Catenin, N-Cadherin, ZO1, as marked by white arrows (**o--q**) and asterisk (**r**). bv -- blood vessels. Scalebars: 20 μm (**b--i,k--r**). See also [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.](elife-45961-fig4){#fig4}

Focal increases in nuclear yap (nYap) and neural progenitors at the mutant ventricular edge corresponded to gyrification zones {#s2-5}
------------------------------------------------------------------------------------------------------------------------------

Forebrain ependymal development is normally initiated in mouse during mid-gestation ([@bib26]). Our analysis of ependymal markers (Yap, Vimentin, Six3) indicated clear abnormalities in mutant mice ([@bib54]; [@bib32]; [@bib44]). Especially striking were alterations in the localization of Yap, a molecule that sits at the nexus of multiple signaling pathways and that is normally expressed in blood vessels and at the ZO1^+^ apical membrane of differentiating ependymal cells ([Figure 5b,c,o--p,s,s'](#fig5){ref-type="fig"}). At P3, numerous ectopic Yap^+^ cells were distributed distal to the mutant CA1 ventricular edge, particularly predominant in the developing gyri ([Figure 5e,i,m](#fig5){ref-type="fig"}). At E16.5, we observed focal concentrations of Yap^+^ cells in the unzippered areas of the mutant ventricular lining; subtle focal disruption was evident as early as E14.5 ([Figure 5q,t](#fig5){ref-type="fig"}). Notably, Yap localization was predominantly cytoplasmic (cYap) and apical at all stages in control mice. In mutants however, we observed aberrant nuclear localization of Yap at all stages, especially evident at P3. The total number of nYap^+^ cells is significantly higher in P3 mutant sulcus and gyrus, compared with the controls (p\<0.0001, [Figure 5l](#fig5){ref-type="fig"}). Magnified images of E16.5 and E14.5 mutant apical edges displayed a more frequent presence of nYap^+^ cells, compared to the respective controls ([Figure 5o',q',s',t'](#fig5){ref-type="fig"}). Disruption of ependymal development was also supported by altered expression of Vimentin and Six3 expression in the mutant ([Figure 5d,h,k](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1a--d](#fig5s1){ref-type="fig"}).

![Embryonic induction of *Pik3ca^H1047R^* mutation disrupts early developing ependyma and induces increase in nYap^+^ cells.\
(**a,n**) Schematics of P3, E16.5 and E14.5 hemi-sections; boxed regions depict areas of interest. (**b-d,o,o'p,s,s'**) Ependymal markers Yap and Vimentin, and junction protein ZO-1 are localized at the apical lining of P3, E16.5 and E14.5 control CA1 respectively. Additionally, Yap and ZO-1 mark the blood vessel membranes (bv), while Vimentin mark the hippocampal radial glia. (**e**) P0 mutant CA1 gyral ventricular lining showed presence of focal nYap-enriched zones (arrowheads, orange box), interspersed by Yap-sparse zones at the sulci (cyan box). (**f,i**) Increased Yap^+^ nuclei in P3 mutant gyri (open arrowheads) and Yap-sparse mutant sulcus edge (asterisks) indicated disrupted ependyma. (**g,j**) ZO-1 was ectopically expressed in P3 mutant gyral ventricular zone, with breaks in the sulcus areas. (**h,k**) Vimentin^+^ fibers appeared to be arranged in an hour-clock pattern at the gyri; sulci demonstrated more disoriented fibers and gaps (asterisk); dashed lines mark the basal ependymal edge. (**l,m**) Total number and distribution of nYap^+^ cells in the different CA1 subzones (binned as mono-layer apical edge, ventricular-subventricular zone (vz/svz), white matter (wm) and CA1 pyramidal layer (CA1 PL)) were significantly enhanced in P3 mutant, compared to control littermates (total counts: F = 179.1, df = 28; cell distribution: F = 137.8, df = 86). The control CA1 showed minimal existence of nYap^+^ cells beyond the vz/svz. Data are represented as mean ± SEM in scatter plots (**l**) or 100% stacked columns (**m**); one-way and two-way ANOVA were performed respectively. (**o--q'**) Compared with control, E16.5 *Pik3ca^H1047R^* mutant showed abnormal zippering of forebrain apical membranes, combined with focal nYap expression (arrowheads). (**s--t'**) Compared with control, E14.5 mutant medial apical membrane showed subtle disruption of cell adhesion causing minor buckling/unevenness. Magnified images of E14.5 and E16.5 ventricular edge demonstrated higher number of nYap^+^ cells in the mutant (yellow dotted lines) compared to controls (**o',q',s',t'**); some non-nYap^+^ cells are marked with pink dotted lines for the purpose of comparison (**o',s',t'**). Scale bars: 20 μm (**b--d, f--k, o--t**), 500 μm (**e**), 10 μm (**o',q',s',t'**). See also [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}.](elife-45961-fig5){#fig5}

Inhibition of nYap attenuated gyrification and rescued ventriculomegaly {#s2-6}
-----------------------------------------------------------------------

In neural stem cells, nYap drives proliferation and cYap acts to stabilize apical adherens junctions ([@bib44]; [@bib31]). We therefore hypothesized that focal nuclear mis-localization of Yap, from cytoplasm to nucleus, in the early mutant ventricular zone, drives focal over-proliferation and disrupts apical cell adhesion at nascent mutant gyri. To test this hypothesis, we administered nYap inhibitor verteporfin ([@bib59]; [@bib53]; [@bib35]), by intraperitoneal injection to pregnant dams (doxycycline: E13.5 \> E15.5; verteporfin: daily E13.5 \> E18.5; [Figure 6a](#fig6){ref-type="fig"}). Morphological analysis at P0 confirmed that verteporfin treatment indeed attenuated the Pik3ca-related gyrification severity and completely rescued ventriculomegaly in 100% of the mutant brains, with little effect on control CA1 ventricular-subventricular zone morphology ([Figure 6b--g](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1a--h,j](#fig6s1){ref-type="fig"}).

![Translocation of Yap from nucleus to cytoplasm by verteporfin attenuates gyrification and ventriculomegaly in *Pik3ca^H1047R^* mutant.\
(**a**) Developmental timeline of verteporfin administration (E13.5 \> E18.5). (**b--d**) Nissl-staining revealed attenuation of gyrification and absence of ventriculomegaly in P0 *Pik3ca^H1047R^* mutant (induced E13.5 \> E15.5) post-verteporfin administration. Boxes mark the respective areas of interest for (**e--g**). (**e--g**) Flowchart of laser capture microdissection (LCM) of marked ventricular-subventricular zone tissue samples, and RNA sequencing. Asterisks (**c,f**) mark neocortical gyrification in the untreated mutant brains, that were also eventually attenuated by verteporfin (**d,g**). (**h**) Principal component (PC) analysis revealed that verteporfin administration drives ventricular *Pik3ca* mutant gene expression towards that of control tissue. PC1 is largely explained by PI3K signaling, PC2 by Hippo-Yap signaling. (**i**) Graphs showing the effect of PI3K overactivation and of verteporfin treatment in *Pik3ca*. Scale bars: 1 mm (**b--d**), 500 μm (**e--g**). See also [Figure 6---figure supplements 1](#fig6s1){ref-type="fig"}--[3](#fig6s3){ref-type="fig"}, [Figure 6---source datas 1](#fig6sdata1){ref-type="supplementary-material"} and [2](#fig6sdata2){ref-type="supplementary-material"}.\
10.7554/eLife.45961.020Figure 6---source data 1.Significant gene list and differential expression analysis from P0 *Pik3ca^H1047R^* mouse RNA-seq data.A truncated gene list is shown based on selected parameters (logFC \>0.263, FDR \< 0.05, true for at least one biological pair comparison).\
10.7554/eLife.45961.021Figure 6---source data 2.Gene lists used in gene set enrichment analyses.](elife-45961-fig6){#fig6}

Using laser-capture method, we micro-dissected ventricular regions of the hippocampi from verteporfin treated and untreated mice, isolated RNA and performed RNA sequencing. Principal component analysis of the global transcriptional profiles of laser micro-dissected P0 CA1 ventricular-subventricular zone tissue ([Figure 6e--i](#fig6){ref-type="fig"}) confirmed that the untreated *Pik3ca* mutant samples (both gyrus and sulcus) were clearly distinct from the control samples. Verteporfin treatment had minimal effect on gene expression of control tissue but shifted the mutant gene expression profiles towards controls. Specifically, verteporfin treatment caused the mutant sulcus samples to cluster together with control samples, while treated mutant gyrus samples showed evidence of partial normalization. As expected, *Pik3ca* expression was higher in mutant samples, and suppressed post-verteporfin treatment, reflecting the complex feedback signaling in the PI3K pathway ([@bib7]). Gene set enrichment analysis confirmed that PI3K and Hippo-Yap signaling pathways were significantly differentially regulated in untreated mutants compared to controls, as expected ([Figure 6---figure supplement 2a--d](#fig6s2){ref-type="fig"}, [Figure 6---source datas 1](#fig6sdata1){ref-type="supplementary-material"} and [2](#fig6sdata2){ref-type="supplementary-material"}). Verteporfin treatment brought both PI3K and Hippo-Yap gene expression in mutants close to control levels, especially at the sulci. Notably, there was a considerable overlap in the gyral and sulcal gene expression profiles of our *Pik3ca^H1047R^* mutant mice and those mapped from ferret ([@bib11]) -- a naturally gyrencephalic mammal ([Figure 6---figure supplement 3a,b](#fig6s3){ref-type="fig"}). These suggest that our activating *Pik3ca* mutant gyrification model has significant physiological relevance to at least this naturally gyrencephalic species.

Immunohistochemical analyses of P0 verteporfin-treated mutants revealed normalized apical cell polarity in both the regions of attenuated sulci and gyri, with elimination of ectopic nYap^+^ cells and rescue of contiguous apical ZO1 and cYap localization ([Figure 7b,c,h--i',n--o'](#fig7){ref-type="fig"}). Verteporfin normalized both nYap^+^ and Six3^+^ cell number and distribution in P0 mutant gyri and sulci ([Figure 6---figure supplement 1k,l](#fig6s1){ref-type="fig"}; [Figure 7h',n',t,u](#fig7){ref-type="fig"}). The 5 day acute verteporfin treatment of mutant mice resulted in streamlined Vimentin^+^/Nestin^+^ radial glia, denser CA1 PL cell packing and reduction in the Tbr2^+^ basal progenitor pool to almost control levels ([Figure 7d--g,j--m',p--s',v](#fig7){ref-type="fig"}). Restoration of P0 mutant ventricular cell polarity was readily apparent with β-Catenin and N-Cadherin expression, which also highlighted the close apposition of the neocortical and hippocampal ependymal surfaces ([Figure 7---figure supplement 1a--i'](#fig7s1){ref-type="fig"}). The effect of verteporfin on tissue architecture was identifiable even early, as studied in E16.5 *Pik3ca^H1047R^* mutants and control littermates ([Figure 7---figure supplement 2a--c](#fig7s2){ref-type="fig"}). Compared to the untreated mutants, E16.5 verteporfin-treated mutants (verteporfin: E13.5 \> E16.5) demonstrated increased alignment of junctional proteins, normalized progenitor pool numbers and reduced occurrence of unzippered apical membranes ([Figure 7---figure supplement 2d--g'](#fig7s2){ref-type="fig"}). TUNEL assay showed no significant difference in apoptotic cell number between E16.5 control and mutant CA1, both in untreated and in verteporfin-treated conditions, indicating that cell death is not an important factor influencing the mutant phenotypes ([Figure 7---figure supplement 2h](#fig7s2){ref-type="fig"}). The effect of PI3K-Yap interactions on cell adhesion and proliferation is summarized in [Figure 8a--c](#fig8){ref-type="fig"}.

![Reduction of nYap by verteporfin re-establishes developing apical junctions and suppresses focal proliferation in *Pik3ca^H1047R^* mutant.\
(**a**) Schematics of P0 control and mutant (±verteporfin) forebrain hemi-sections; boxes depict respective areas of interest. (**b--g**) P0 control untreated brain expressed cYap, adherens junction protein ZO-1 and radial glial markers Vimentin and Nestin, uniformly along the juxtaposed apical membranes. Ctip2 and Tbr2 were expressed in pyramidal neurons and IPs respectively. (**h--s'**) Verteporfin treatment significantly normalized Yap localization, from nucleus to cytoplasm, restored apical junctions and streamlined disrupted radial glial scaffold, as compared to the untreated P0 (dox E13.5 \> E15.5) mutant gyri and sulci. (**t,u**) The treatment significantly reduced the total nYap^+^ cell number in the mutant hippocampal gyri and sulci (F = 70.47, df = 32) as well as normalized the nYap^+^ cell distribution to the control levels (F = 134.4, df = 96). This also significantly decreased the Tbr2^+^ progenitor population (F = 31.45, df = 35), especially in the mutant gyral zones, as quantitated in (**v**). This resulted in attenuation of the extent of gyrification and re-zippering of the apical membranes to halt the progressive ventriculomegaly. Data are represented as mean ± SEM in scatter plots (**t**); two-way ANOVA was followed by Tukey's post-tests. ns, not significant. Open arrowheads, disrupted/ectopic junctional and ependymal proteins in mutant; asterisks, absence of adhesion/ependymal molecules at the mutant apical edge; arrowheads, rescued apical ventricular lining in the mutant post-verteporfin treatment; bv, blood vessels; LV, lateral ventricle. Scalebars: 20 μm (**b--s'**). See also [Figure 7---figure supplements 1](#fig7s1){ref-type="fig"}--[2](#fig7s2){ref-type="fig"}.](elife-45961-fig7){#fig7}

![Summary: PI3K-Yap gyrification model.\
(**a**) Schematic of PI3K-AKT-MTOR pathway, its connection with Yap signaling and mode of verteporfin action. The activity of the PI3K enzyme (dimer of catalytic and regulatory subunits) initiates the PI3K-AKT-MTOR pathway cascade. In parallel, downstream of the Hippo pathway, Yap binds to transcriptional regulator proteins in the nucleus, to facilitate cell growth and proliferation. Activation of Hippo pathway results in translocation of nuclear Yap to cytoplasm through phosphorylation. Cytoplasmic Yap, in turn, promotes cell adhesion. The activating *Pik3ca* mutation results in Yap translocation from cytoplasm to nucleus, possibly via Pdk1. In this study, verteporfin, a nuclear Yap inhibitor, restored cytoplasmic Yap. (**b,c**) Schematics summarizing main findings of the paper: PI3K over-activation resulted in disruption of cell adhesion at the neural-ependymal transition zone causing ventriculomegaly, and also in differential proliferation of progenitors, thus triggering the gyrification sequence cascade (effect of genotype). In mutant mice, verteporfin attenuated these anomalies (effect of drug), leading to reduction in gyrification severity as well as ventriculomegaly. Area within the yellow dashed boxes in the top rows of (**b**) and (**c**) is magnified in the respective bottom rows. Color coding for elements in (**b**) and (**c**) is explained in the figure 'key'. vz/svz, ventricular/subventricular zone.](elife-45961-fig8){#fig8}

Discussion {#s3}
==========

Cortical gyrification or its absence is an essential feature of mammalian brain evolution but the mechanisms driving cortical folding, particularly its initiation, are poorly understood ([@bib4]). Using our activating *Pik3ca* mutant mouse model of human cortical malformations ([@bib52]), we have established that regulated cell adhesion and proliferation via PI3K-Yap signaling at the apical edge of the embryonic ventricular zone is critical to maintain the lissencephalic nature of mouse brain and prevent developmental hydrocephalus. Overactivation of PI3K signaling in neural progenitors during a critical embryonic period (E13.5-E15.5) led to 'true' gyrification ([@bib4]) of the mutant mouse neocortex and hippocampus, with the stereotypic characteristics of folded pial surface and neuronal plate/white matter of differential thickness, with predominantly smooth apical ventricular surfaces. This transient PI3K activation was also sufficient to initiate a stereotypic neurogenic sequence similar to that seen in naturally gyrencephalic mammals, such as ferrets ([@bib48]; [@bib11]). This sequence includes differential proliferation of primary and secondary (IPs, bRGs) progenitors, cell differentiation and migration, and an altered radial glial scaffold. PI3K overactivation did not disrupt gross hippocampal patterning but did cause subtle disruptions in cell adhesion at the apical edge. Adhesion abnormalities were concurrently associated with aberrant focal cytoplasmic-to-nuclear translocation of Yap protein, which predicted the stereotypical positioning of the gyral foci. Hydrocephalus in this model was also associated with the disruption of PI3K-dependent apical adhesion in the same progenitors, but across a broader embryonic time-period. Both the gyrification and hydrocephalic phenotypes were 100% penetrant in the mutants and were attenuated by embryonic treatment with verteporfin, a nYap inhibitor, which normalized apical junctions and proliferation along the mutant ventricular linings. Our data provide new insights regarding the mechanisms that initiate gyrification in mammals, and apical adhesion alterations in human PI3K-related disorders that contribute to the broad range of neuropathology including impaired brain folds and ventriculomegaly.

*Pik3ca* mis-regulation altered cell adhesion at the apical edge of cortical ventricular zone {#s3-1}
---------------------------------------------------------------------------------------------

Brief activation of the *Pik3ca^H1047R^* mutation resulted in focal disruption of adhesion, as observed in the loose 'zippering' of the ventricular linings, subtle initial changes and then gaps in the expression of adhesion molecules β-Catenin, N-Cadherin and ZO-1, especially in the prospective sulci. This in turn impinged on the development of neuronal and ependymal progenitors. Interestingly, the developing ferret brain also demonstrates differential regional variation in cell adhesion and junctional proteins at the prospective gyrus and sulcus ([@bib11]). Genes that were differentially expressed between the gyrus and sulcus in ferret were enriched in our *Pik3ca^H1047R^* mutant, with considerable overlap in cell adhesion-related genes. This demonstrates potential physiological relevance of our model to naturally gyrencephalic mammals, although additional experiments may be required.

The ventricular surface of the developing brain is formed by tangential assembly of the apical end-feet of progenitor cells, enriched in adherens junction molecules, ZO-1 and Cadherins ([@bib42]). Loss-of-function mutations in the cell adhesion machinery, such as *fyn*, *Cdh2* (N-Cadherin) cause dysplastic hippocampal morphology ([@bib17]; [@bib27]). Recently, adhesion-ECM molecules, like E-cadherin, connexins, FLRT1/3, filamin, have been identified, that influence the balance in adhesion-repulsion forces between migrating neurons to cause interspersed cell clustering with differential migration speed, eventually establishing the cortical sulci ([@bib4]; [@bib36]). It is interesting to note that all these molecules have well-established functional interactions with the PI3K pathway ([@bib16]; [@bib56]; [@bib43]; [@bib23]; [@bib38]).

Perhaps the closest published model to our new *Pik3ca^H1047R^* mouse model is the *D6-cre;Cdh2* conditional knockout ([@bib27]), which exhibited folding in the CA1 PL. However, the loss of N-Cadherin in early differentiating neurons induced complete disruption of adherens junctions, resulting in abnormalities of internal cortical structures, dysplastic radial glial architecture and cellular lamination, and blurring of the lateral neocortex--hippocampus delineation. Such severe developmental defects are neither observed in normal gyrencephalic mammals nor in our mutant mouse model. Rather in our model, Pik3ca activation caused much more subtle disruption of apical junctions, resulting in cortical folding with broadly normal lamination, as observed in naturally gyrencephalic animals.

The PI3K enzyme is composed of p110 (encoded by *Pik3ca*) and p85 subunits ([@bib15]), Previous studies have demonstrated that *Pik3ca^H1047R^* allele remains tightly dependent on p85 regulation ([@bib15]; [@bib61]; [@bib52]). Hence, although the *Pik3ca^H1047R^* allele is a strongly activating mutation with higher kinase activity ([@bib21]), it is functionally not an overexpression allele to cause massive pathway induction. Taken together, our data indicate that exquisite PI3K-dependent regulation of apical cell adhesion is essential for normal mouse brain development and suggests that subtle regional changes in other mammals may initiate natural gyrification. This hypothesis should be readily testable but is beyond the scope of our current study.

PI3K-dependent modulation of Yap protein function is central to initiation of gyrification {#s3-2}
------------------------------------------------------------------------------------------

Focal loss of apical integrity and over-proliferation of neural progenitors in our *Pik3ca* model highly correlated with focal areas of translocation of Yap protein from the apical cytoplasmic edge to nuclei at the ventricular lining. Yap is a central regulator of the Hippo pathway, with both nuclear and cytoplasmic functions ([@bib20]; [@bib44]; [@bib45]). The Hippo-Yap pathway is known to mediate mechanical signals, cellular stress, polarity and adhesion cues that are integrated through multiple upstream regulators ([@bib22]). Phosphorylated Yap is sequestered in the cytoplasm by adherens junction proteins. In turn, cYap, expressed in the early developing ependyma, has been shown to critically maintain cell-cell adhesion at the ventricular edge of ventral aqueduct ([@bib44]). When dephosphorylated, Yap translocates to the nucleus, where it binds to TEAD transcriptional co-regulators to modulate gene expression ([@bib22]; [@bib45]). In this context, nYap was recently shown to be sufficient to drive cortical progenitor proliferation ([@bib31]).

We hypothesized that PI3K regulation of Yap subcellular distribution was central to the gyrification phenotype in our *Pik3ca^H1047R^* mutant mouse model. *In vitro*, PI3K-PDK1 pathway activation promotes nuclear translocation of Yap, thus disrupting contact inhibition ([@bib12]). Verteporfin, a nYap antagonist, disintegrates the Yap-TEAD nuclear complex, facilitating sequestration of Yap to the cytoplasm ([@bib59]; [@bib53]; [@bib35]; [@bib12]; [@bib5]; [@bib20]). Treatment of *Pik3ca^H1047R^* mutants with verteporfin restored the apical cYAP distribution in progenitors, rescued the integrity of the ventricular surface, reduced the enhanced progenitor proliferation and subsequently attenuated the gyrification of the *Pik3ca^H1047R^* mutant mice. To our knowledge, this is the first study where verteporfin was introduced intraperitoneally into the pregnant mice to successfully suppress nYap function in embryos across the placental barrier.

We did not fully rescue the gyrification phenotype, likely because PI3K signaling has a multitude of downstream outputs in addition to Yap regulation. Although we cannot rule out potential off-target effects of verteporfin, our data provide strong evidence that PI3K pathway modulation of the cYap pool during the brief embryonic critical period is essential to maintain the lissencephalic mouse brain. We speculate that subtle changes in local apical adhesion properties of early progenitors, associated with focal changes in Yap subcellular distribution and subsequently in the basal progenitor population, is one of the initiating mechanisms of gyrification in higher mammals. This may also be linked to changes in centrosome and microtubule organization in apical progenitors ([@bib6]). Further, a recent study has demonstrated that YAP maintains basal progenitor population in the developing ferret and human neocortex ([@bib30]). Similar to our current findings, this study also showed that YAP regulation by verteporfin in *ex vivo* embryonic ferret and fetal human neocortical free-floating tissue culture systems leads to reduction in basal progenitor number ([@bib30]). However, further analysis of all these parameters in ferrets ([@bib4]) and other model systems is required.

Cortical folding patterns in naturally gyrencephalic species are highly stereotypic, although there is considerable inter-individual variation ([@bib51]; [@bib4]). Importantly, the gyrification pattern induced in *GFAP-cre;Pik3ca^H1047R^* mutants was non-random, with 100% penetrance, and was highly cre-dependent ([@bib52]; [@bib9]). We do not currently understand why gyri form in stereotypical positions in *Pik3ca^H1047R^* mutant mice or indeed, in any normal gyrencephalic mammal. We hypothesize that cell-cell adhesion is less constrained in susceptible focal positions compared to adjacent regions during the critical periods of development. These coordinates may be defined by genetically encoded signaling gradients or may simply be a result of regional variations in mechanical force ([@bib51]; [@bib4]). Developing cortical tissue from naturally gyrencephalic mammals is of limited availability, making extensive experimentation difficult. The highly regulatable stereotypical and fully penetrant gyrification phenotype of *Pik3ca^H1047R^* mutant mice provides a new, highly tractable alternative model to unravel the positional constraints giving rise to brain folds.

Yap-dependent apical cell adhesion mediates normal ependymal development and its disruption likely underlies multiple types of pediatric hydrocephalus amenable to small molecule therapy {#s3-3}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In addition to gyrification, embryonic induction of *Pik3ca^H1047R^* allele in mouse neural progenitors also caused ventriculomegaly which progressed postnatally to hydrocephalus. Hydrocephalus is a common feature of human PI3K-related brain overgrowth syndromes ([@bib40]; [@bib58]; [@bib19]; [@bib29]). We determined that PI3K-dependent ventriculomegaly had long embryonic critical period, ending at E17.5, compared to the short gyrification critical period (E13.5-E15.5). Embryonic verteporfin-dependent nYap inhibition also rescued ventriculomegaly, with minimal effect on control littermates. We conclude that disrupted apical cell adhesion and aberrant nYap localization were central to this phenotype as well as gyrification.

Hydrocephalus is often associated with a disrupted ependyma, although in many cases it is unclear if this is because of abnormal ependymal development or ependymal damage at a later stage ([@bib26]). The ependyma is a continuous single layer of neuroepithelial multi-ciliated cells lining the lateral ventricles. Ependymal cells differentiate from apical progenitors and mature during late embryogenesis and early postnatal mouse development, when most definitive ependymal markers, including FoxJ1 and other markers of multi-ciliated cells, are expressed ([@bib53]; [@bib32]). Little is understood regarding the primary molecular control of ependymal specification. In our mutant mouse model, the normally uniform layer of Vimentin^+^/Yap^+^ developing ependymal cells was disrupted at mid-embryonic stages. Further, cells with ependymal fate (Yap^+^) were intermingled with Tbr2^+^ progenitors and young Ctip2^+^ neurons at the mutant gyral edge, indicating abnormal neural-to-ependymal transition. This phenotype and the subsequent hydrocephalus were reversed with verteporfin treatment, although the drug-treated ependyma was not entirely normal. These data clearly demonstrate that early Yap-dependent apical adhesion is required for normal ependymal development in forebrain during embryonic pre-ciliogenesis stages -- a developmental time much earlier than previously established.

Interestingly, human post-mortem studies and *in vitro* model studies have shown disruption of cell adhesion and apical junctions in post-hemorrhagic hydrocephalus, a common form of hydrocephalus in premature infants, currently with few treatment options ([@bib41]; [@bib26]; [@bib19]). In mice, embryonic intraventricular administration of blood-derived lysophosphatidic acid (LPA), is sufficient to cause disrupted ependymal cell adhesion and neonatal hydrocephalus in mice ([@bib60]). More recently, [@bib44] showed that depletion of cYAP, by either genetic deletion or LPA treatment, also resulted in perinatal hydrocephalus due to impaired ependymal development and aqueduct blockage ([@bib44]). Taken together with our data, we posit that altered periventricular cell adhesion caused by dysregulated Hippo-Yap signaling is a common convergent mechanism for both developmental and post hemorrhagic hydrocephalus. Fine regulation of the Hippo-Yap pathway may represent a new therapeutic approach for pediatric hydrocephalus patients, especially since verteporfin effectively crosses the placenta and has minimal effect on normal brain development as demonstrated by our morphological and RNA-seq analyses. This implication is worthy of further detailed preclinical analysis.

In summary, building upon our original study of mouse models of human *PIK3CA*-related brain malformations ([@bib52]), we demonstrate intimate PI3K-dependent developmental and molecular links between cortical neurogenesis and ependymal development at the apical edge of the embryonic ventricular zone. Disruption of apical surface integrity in the forebrain, via enhanced embryonic PI3K-Yap signaling, alters neurogenesis and can initiate *bona fide* gyrification in mice. This process mimics the canonical neurogenic sequence observed in naturally gyrencephalic mammals. Concurrently, abnormal apical PI3K-Yap interaction disrupts ependymal development in forebrain, prior to ciliogenesis, leading to hydrocephalus. Our data readily explain the coincidence of impaired neurogenesis, gyrification and hydrocephalus, observed often in patients with cortical dysplasia and in our *Pik3ca* mouse model ([@bib28]; [@bib24]; [@bib52]; [@bib46]; [@bib14]). The results also provide support for nuclear Yap protein as a potential new therapeutic target for these clinically important disorders.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\      Designation                      Source or\                                                                                 Identifiers                                                                           Additional information
  (species) or\                                       reference                                                                                                                                                                        
  resource                                                                                                                                                                                                                             
  ------------------ -------------------------------- ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------- ----------------------------------------------------------------
  Genetic reagent\   *GFAP-cre*                       gift (JJ Zhao); PMID: [11668683](http://www.ncbi.nlm.nih.gov/pubmed/11668683)              (IMSR Cat\#\                                                                          gifted by Dr. Jean J\
  (*Mus musculus*)                                                                                                                               JAX:004600,\                                                                          Zhao (Dana Farber Cancer\
                                                                                                                                                 RRID:[IMSR_JAX:004600](https://scicrunch.org/resolver/IMSR_JAX:004600))               Inst., Boston, USA)

  Genetic reagent\   *Pik3ca^H1047R^*                 gift (JJ Zhao); PMID: [21822287](https://www.ncbi.nlm.nih.gov/pubmed/21822287)             MGI: 5526971                                                                          gifted by Dr. Jean J\
  (*Mus musculus*)                                                                                                                                                                                                                     Zhao (Dana Farber\
                                                                                                                                                                                                                                       Cancer Inst., Boston, USA)

  Genetic reagent\   *Ai14/+; Ai14*                   Jax labs (stock \#007914), PMID:[20023653](https://www.ncbi.nlm.nih.gov/pubmed/21822287)   (IMSR Cat\# JAX:007914,\                                                              PMID: [20023653](https://www.ncbi.nlm.nih.gov/pubmed/20023653)
  (*Mus musculus*)                                                                                                                               RRID:[IMSR_JAX:007914](https://scicrunch.org/resolver/IMSR_JAX:007914))               

  Genetic reagent\   *Rosa26-rtTA; Rosa*              PMID: [15784609](http://www.ncbi.nlm.nih.gov/pubmed/15784609)                              (IMSR Cat\# JAX:005670,\                                                              gifted by Dr. Jean\
  (*Mus musculus*)                                                                                                                               RRID:[IMSR_JAX:005670](https://scicrunch.org/resolver/IMSR_JAX:005670))               J Zhao (Dana Farber\
                                                                                                                                                                                                                                       Cancer Inst., Boston, USA)

  Antibody           Anti-BrdU antibody\              Abcam                                                                                      (Abcam Cat\# ab6326,\                                                                 IHC (1:100)
                     \[BU1/75 (ICR1)\]                                                                                                           RRID:[AB_305426](https://scicrunch.org/resolver/AB_305426))                           

  Antibody           Anti-BrdU-Fluorescein\           Roche                                                                                      (Roche Cat\# 11202693001,\                                                            IHC (1:100)
                     antibody Formalin\                                                                                                          RRID:[AB_514484](https://scicrunch.org/resolver/AB_514484))                           
                     grade                                                                                                                                                                                                             

  Antibody           Rabbit anti Calbindin\           Swant                                                                                      (Swant Cat\# CB38,\                                                                   IHC (1:1500)
                     D-28k                                                                                                                       RRID:[AB_2721225](https://scicrunch.org/resolver/AB_2721225))                         

  Antibody           Anti-Ctip2 antibody\             Abcam                                                                                      Abcam Cat\# ab18465,\                                                                 IHC (1:250)
                     \[25B6\] - ChIP Grade                                                                                                       RRID:[AB_2064130](https://scicrunch.org/resolver/AB_2064130))                         

  Antibody           Rabbit GFAP antibody             Dako (now Agilent)                                                                         (Agilent Cat\# Z0334,\                                                                IHC (1:2500)
                                                                                                                                                 RRID:[AB_10013382](https://scicrunch.org/resolver/AB_10013382))                       

  Antibody           Anti-Neural Cell Adhesion\       Millipore                                                                                  (Millipore Cat\# MAB5272,\                                                            IHC (1:200)
                     Molecule L1 Antibody,\                                                                                                      RRID:[AB_2133200](https://scicrunch.org/resolver/AB_2133200))                         
                     clone 324                                                                                                                                                                                                         

  Antibody           Rabbit Anti-Laminin              Sigma                                                                                      (Sigma-Aldrich\                                                                       IHC (1:25)
                                                                                                                                                 Cat\# L9393,\                                                                         
                                                                                                                                                 RRID:[AB_477163](https://scicrunch.org/resolver/AB_477163))                           

  Antibody           Purified Mouse\                  BD Biosciences                                                                             (BD Biosciences\                                                                      IHC (1:150)
                     Anti-N-Cadherin                                                                                                             Cat\# 610921,\                                                                        
                                                                                                                                                 RRID:[AB_398236](https://scicrunch.org/resolver/AB_398236))                           

  Antibody           Mouse Anti-Nestin\               Millipore                                                                                  (Millipore\                                                                           IHC (1:200)
                     Antibody, clone rat-401                                                                                                     Cat\# MAB353,\                                                                        
                                                                                                                                                 RRID:[AB_94911](https://scicrunch.org/resolver/AB_94911))                             

  Antibody           Rabbit Purified\                 Biolegend                                                                                  (BioLegend\                                                                           IHC (1:300)
                     anti-Pax-6 Antibody                                                                                                         Cat\# 901301,\                                                                        
                                                                                                                                                 RRID:[AB_2565003](https://scicrunch.org/resolver/AB_2565003))                         

  Antibody           Mouse anti-Pax6\                 DSHB                                                                                       N/A                                                                                   IHC (1:300; deposited\
                     antibody                                                                                                                                                                                                          in DSHB by Kawakami A.)

  Antibody           Phospho-Histone\                 Cell Signaling                                                                             (Cell Signaling\                                                                      IHC (1:200)
                     H3 (Ser10) (6G3)\                                                                                                           Technology Cat\# 9706,\                                                               
                     Mouse mAb                                                                                                                   RRID:[AB_331748](https://scicrunch.org/resolver/AB_331748))                           

  Antibody           Anti-Reelin Antibody,\           Millipore                                                                                  (Millipore Cat\#\                                                                     IHC (1:1200)
                     a.a. 164--496 mouse\                                                                                                        MAB5364,\                                                                             
                     reelin, clone G10                                                                                                           RRID:[AB_2179313](https://scicrunch.org/resolver/AB_2179313))                         

  Antibody           Anti-SATB2 antibody\             Abcam                                                                                      (Abcam Cat\# ab51502,\                                                                IHC (1:400)
                     \[SATBA4B10\] - C-terminal                                                                                                  RRID:[AB_882455](https://scicrunch.org/resolver/AB_882455))                           

  Antibody           Rabbit anti-Six3\                Rockland\                                                                                  (Rockland Cat\#\                                                                      IHC (1:200)
                     polyclonal antibody;             Antibodies                                                                                 600--401-A26S,\                                                                       
                                                                                                                                                 RRID:[AB_11181864](https://scicrunch.org/resolver/AB_11181864))                       

  Antibody           Rabbit anti-Sox2\                Thermo Fisher\                                                                             (Thermo Fisher\                                                                       IHC (1:400)
                     antibody                         Scientific                                                                                 Scientific Cat\# PA1-094,\                                                            
                                                                                                                                                 RRID:[AB_2539862](https://scicrunch.org/resolver/AB_2539862))                         

  Antibody           Rabbit anti-Tbr1\                Millipore                                                                                  (Millipore Cat\#\                                                                     IHC (1:400)
                     antibody                                                                                                                    AB10554, RRID:[AB\_](https://scicrunch.org/resolver/AB_10806888)\                     
                                                                                                                                                 [10806888](https://scicrunch.org/resolver/AB_10806888))                               

  Antibody           EOMES Monoclonal\                eBioscience                                                                                (Thermo Fisher\                                                                       IHC (1:200)
                     Antibody (Dan11mag)\                                                                                                        Scientific Cat\# 14-4875-82,\                                                         
                     Tbr2 antibody                                                                                                               RRID:[AB_11042577](https://scicrunch.org/resolver/AB_11042577))                       

  Antibody           Anti-Vimentin antibody\          Abcam                                                                                      (Abcam Cat\# ab92547,\                                                                IHC (1:200)
                     \[EPR3776\] - Cytoskeleton\                                                                                                 RRID:[AB_10562134](https://scicrunch.org/resolver/AB_10562134))                       
                     Marker                                                                                                                                                                                                            

  Antibody           YAP (D8H1X) XP\                  Cell Signaling                                                                             (Cell Signaling\                                                                      IHC (1:100)
                     Rabbit mAb                                                                                                                  Technology Cat\#\                                                                     
                                                                                                                                                 14074, RRID:[AB_2650491](https://scicrunch.org/resolver/AB_2650491))                  

  Antibody           ZO-1 Monoclonal\                 Thermo Fisher\                                                                             (Thermo Fisher\                                                                       IHC (1:500)
                     Antibody (ZO1-1A12),\            Scientific                                                                                 Scientific Cat\# 339188,\                                                             
                     Alexa Fluor 488                                                                                                             RRID:[AB_2532187](https://scicrunch.org/resolver/AB_2532187))                         

  Antibody           Purified Mouse\                  BD Biosciences                                                                             (BD Biosciences\                                                                      IHC (1:200)
                     Anti-β-Catenin Clone 14                                                                                                     Cat\# 610154,\                                                                        
                                                                                                                                                 RRID:[AB_397555](https://scicrunch.org/resolver/AB_397555))                           

  Antibody           Rabbit β-Catenin\                Abcam                                                                                      (Abcam Cat\# ab2365,\                                                                 IHC (1:100)
                     antibody                                                                                                                    RRID:[AB_303014](https://scicrunch.org/resolver/AB_303014))                           

  Antibody           Goat anti-Rat IgG\               Thermo Fisher\                                                                             (Thermo Fisher\                                                                       IHC (1:400)
                     (H + L) Cross-Adsorbed\          Scientific                                                                                 Scientific Cat\# A-21247,\                                                            
                     Secondary Antibody,\                                                                                                        RRID:[AB_141778](https://scicrunch.org/resolver/AB_141778))                           
                     Alexa Fluor 647                                                                                                                                                                                                   

  Antibody           Goat anti-Mouse IgG\             Thermo Fisher\                                                                             (Thermo Fisher\                                                                       IHC (1:400)
                     (H + L) Highly Cross-Adsorbed\   Scientific                                                                                 Scientific Cat\# A-11029,\                                                            
                     Secondary Antibody, Alexa\                                                                                                  RRID:[AB_2534088](https://scicrunch.org/resolver/AB_2534088))                         
                     Fluor 488                                                                                                                                                                                                         

  Antibody           Goat anti-Rabbit IgG (H + L)\    Thermo Fisher\                                                                             (Thermo Fisher\                                                                       IHC (1:400)
                     Highly Cross-Adsorbed\           Scientific                                                                                 Scientific Cat\# A-11036,\                                                            
                     Secondary Antibody,\                                                                                                        RRID:[AB_10563566](https://scicrunch.org/resolver/AB_10563566))                       
                     Alexa Fluor 568                                                                                                                                                                                                   

  other              DAPI stain                       Molecular Probes                                                                           (Thermo Fisher\                                                                       1:10000
                                                                                                                                                 Scientific Cat\# D1306,\                                                              
                                                                                                                                                 RRID:[AB_2629482](https://scicrunch.org/resolver/AB_2629482))                         

  Commercial\        ApopTag Plus Fluorescein\        Chemicon/Millipore                                                                         Cat\# S7111                                                                           
  assay or kit       In situ Apoptosis\                                                                                                                                                                                                
                     Detection Kit                                                                                                                                                                                                     

  Commercial\        SMART-Seq v4 Ultra\              Takara                                                                                     Cat\# 634889                                                                          
  assay or kit       Low Input RNA Kit                                                                                                                                                                                                 

  Commercial\        Nextera XT kit                   Illumina                                                                                   Cat\# FC-131--1024                                                                    
  assay or kit                                                                                                                                                                                                                         

  Commercial\        KAPA qPCR complete\              Biorad                                                                                     KK4844 Complete\                                                                      
  assay or kit       kit                                                                                                                         kit 500 × 20 ul reactions                                                             

  Commercial\        RNeasy Micro Kit                 Qiagen                                                                                     Cat\# 74004                                                                           
  assay or kit                                                                                                                                                                                                                         

  Commercial\        Bioanalyzer 6000\                Agilent                                                                                    Cat\# 5067--1513                                                                      
  assay or kit       Pico Kit                                                                                                                                                                                                          

  Chemical\          Verteporfin                      US Pharmacopeial\                                                                          Cat\# 1711461                                                                         
  compound, drug                                      Convention                                                                                                                                                                       

  Chemical\          BrdU Labeling\                   Life Technologies                                                                          Cat\# 000103                                                                          
  compound, drug     Reagent                                                                                                                                                                                                           

  Chemical\          Doxycycline\                     Sigma                                                                                      Cat\# D9891-25G                                                                       
  compound, drug     (doxycycline hyclate)                                                                                                                                                                                             

  Software,\         BioViz3D version 3.1             BioViz3D                                                                                   BioViz3D,\                                                                            
  algorithm                                                                                                                                      RRID:[SCR_017162](https://scicrunch.org/resolver/SCR_017162)                          

  Software,\         salmon aligner\                  PMID: [28263959](https://www.ncbi.nlm.nih.gov/pubmed/28263959)                                                                                                                   
  algorithm          v0.11.3 for R                                                                                                                                                                                                     

  Software,\         Bioconductor tximport\           PMID: [26925227](https://www.ncbi.nlm.nih.gov/pubmed/26925227)                                                                                                                   
  algorithm          package, v1.8.0 for R                                                                                                                                                                                             

  Software,\         Bioconductor edgeR\              PMID: [19910308](https://www.ncbi.nlm.nih.gov/pubmed/19910308)                             ([Bioconductor](http://www.bioconductor.org/),\                                       Software
  algorithm          package v3.22.3                                                                                                             RRID:[SCR_006442](https://scicrunch.org/resolver/SCR_006442))                         

  algorithm          glmTreat function\               PMID: [19176553](https://www.ncbi.nlm.nih.gov/pubmed/19176553)                                                                                                                   
                     in edgeR                                                                                                                                                                                                          

  Software,\         Bioconductor GEOquery\           PMID: [17496320](https://www.ncbi.nlm.nih.gov/pubmed/17496320)                             ([GEOquery](http://www.bioconductor.org/packages/release/bioc/html/GEOquery.html),\   
  algorithm          v2.48.0                                                                                                                     RRID:[SCR_000146](https://scicrunch.org/resolver/SCR_000146))                         

  Software,\         limma packages,\                 PMID: [25605792](https://www.ncbi.nlm.nih.gov/pubmed/25605792)                                                                                                                   
  algorithm          v3.36.2 for R                                                                                                                                                                                                     
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

The following mouse lines were used: human glial fibrillary acidic protein (*hGFAP*)*-cre* (Jackson Labs, IMSR Cat\# JAX:004600, RRID:[IMSR_JAX:004600](https://scicrunch.org/resolver/IMSR_JAX:004600)) ([@bib62]), mentioned as *GFAP-cre* in this study; *Pik3ca^H1047R^* transgenic (human *Pik3ca^H1047R^* transgene expression is under the control of a tetracycline-inducible promoter (TetO)), *Rosa26-rtTA* line (Jackson Labs, Stock \#005670) ([@bib3]), Ai-14 (Jackson Labs, Stock \#007914) ([@bib37]).

All lines were maintained on a mixed genetic background, comprising of FVB, 129 and CD1 strains. All mice were housed in Optimice cages with aspen bedding at the Seattle Children's Research Institute's specific pathogen-free (SPF) vivarium facility. Noon of the day of vaginal plug was designated as embryonic day 0.5 (E0.5). The day of birth was designated as postnatal day 0 (P0). The *Pik3ca^H1047R^* and *Rosa26-rtTA* lines were intercrossed and female mice positive for both these alleles were crossed with *GFAP-cre;RosartTA; Pik3ca^H1047R^* males. Embryos or pups of both sexes, genotyped positive for all three genes, namely *cre, Rosa, Pik3ca^H1047R^,* were used in this study. The *GFAP-cre* driver gets activated in neural progenitors only at \~E13 ([@bib62]; [@bib52]). The activating *H1047R* mutation in the PI3K catalytic subunit (*Pik3ca*) increases the level and duration of response to extracellular ligands, its stability being completely dependent on the unaltered level of the p85 regulatory subunit ([@bib52]). To ensure that *cre* and *Pik3ca^H1047R^* mutant transgene expression was correlated, plugged females were treated with doxycycline (Sigma; 2 mg/ml) from E0.5 or as mentioned in the text, available *ad libitum* in drinking water. For the neonatal induction experiment, the pups were treated with doxycycline from P1. The *GFAP-cre;RosartTA;Pik3ca^H1047R^* mutant is mentioned as *Pik3ca^H1047R^* mutant in the text. Mouse genotyping by PCR was done using separate sets of primers for the *Cre* coding region, and the *Pik3ca^H1047R^*, *Rosa+/-*, and *Ai14/+* alleles, as previously described ([@bib52]). All mouse procedures were approved and conducted in accordance with the guidelines laid down by the Institutional Animal Care and Use Committees (IACUC) of Seattle Children\'s Research Institute, Seattle, WA, USA.

Sample preparation and histochemical procedures {#s4-2}
-----------------------------------------------

Embryos and postnatal pups were harvested in phosphate buffer saline (PBS); brains fixed in 4% paraformaldehyde (PFA) for 4 hr, equilibrated in 30% (wt/vol) sucrose made in PBS, and sectioned at 25 μm on a freezing microtome. Sections were then processed for Nissl or immunohistochemical staining. No data were excluded from our analysis and no randomization was used. Tissue collection was not performed blind since the mice were subjected to genotyping and drug administration. However, the data analysis was performed blinded by at least two individuals.

### Immunohistochemistry (IHC) {#s4-2-1}

Sections were washed thrice in PBS, boiled in 10 mM Sodium citrate solution for antigen retrieval, blocked in 5% serum in PBS with 0.1% Triton X-100 and then incubated overnight at 4°C with primary antibodies. The next day, sections were washed thrice in PBS, incubated with appropriate species-specific secondary antibodies conjugated with Alexa 488, 568 or 647 fluorophores (Invitrogen) for 2 hr at room temperature and then counterstained with DAPI (4\',6-Diamidino-2-Phenylindole, Dihydrochloride; Invitrogen; D1306) to visualize nuclei. Sections were cover-slipped using Fluorogel (Electron Microscopy Sciences, EMS \#17985) mounting medium. Immuno-stained sections were imaged in Zeiss LSM 710 Imager Z2 laser scanning confocal microscope using Zen 2009 software and in Olympus VS-120 slide-scanner microscope using Olympus VS-Desktop 2.9 software, and later processed in ImageJ 1.51j8 and ImageJ2 (NIH, Bethesda, Maryland, USA) and Olympus VS-Olyvia 2.9 software programs respectively. Each antibody was validated for mouse and application (IF, IHC) by the correspondent manufacturer, and is publicly available on its website with indicated catalog numbers. This was also validated by us in our experiments, replicating published/expected expression in control tissue. Primary antibodies used: rat anti-BrdU (Abcam), mouse anti-BrdU (Roche), rabbit anti-Calbindin (Swant), rat anti-Ctip2 (Abcam), rabbit anti-GFAP (Dako), rat anti-L1 (Millipore), rabbit anti-Laminin (Sigma), mouse anti-N-Cadherin (BD Biosciences), mouse anti-Nestin (Millipore), rabbit anti-Pax6 (Biolegend), mouse anti-Pax6 (DSHB), mouse anti-phospho-Histone H3 (Cell Signaling), mouse anti-Reelin (Millipore), mouse anti-Satb2 (Abcam), rabbit anti-Six3 (Rockland Antibodies), rabbit anti-Sox2 (Thermofisher), rabbit anti-Tbr1 (Millipore), rat anti-Tbr2 (eBioscience), rabbit anti-Vimentin (Abcam), rabbit anti-Yap (Cell Signaling), mouse anti-ZO-1 (), mouse anti-β-Catenin (BD Biosciences), rabbit anti-β-Catenin (Abcam). Immuno-histochemistry replication consisted of performing the same experiment with biologically independent samples from the same group (control or mutant ±drug). All attempts for replication were successful. No outliers were encountered. Each antibody was validated for mouse and application (IHC) by the correspondent manufacturer and is publicly available on its website with indicated catalog numbers. This was also validated by us in our experiments, replicating published/expected expression in control tissue.

### Nissl staining {#s4-2-2}

Sections were stained in 0.1% cresyl violet solution (Cresyl violet, Sigma Cat\# C5042) for 10 min, rinsed quickly in distilled water, dehydrated in 95% ethanol, and left in xylene before being cover-slipped with Permount (Thermo Fischer Scientific, SP15-500). Brightfield images were taken in the Olympus VS-120 slide-scanner with Hamamatsu digital camera C11440 and processed using the Olympus VS-Olyvia 2.9 software.

BrdU incorporation experiments {#s4-3}
------------------------------

Bromodeoxyuridine (BrdU; Life Technologies) was administered intraperitoneally (100 μg/g of body weight) to pregnant dams at E14.5/16.5 for 1 hr, at E15.5 for 1 day and at E16.5 for proliferation assays, cell cycle exit and birth-dating experiments respectively. Labeling index and quit fraction were calculated as previously described ([@bib52]).

3-D modeling and video {#s4-4}
----------------------

3-D models of P3 (dox E0.5 to P3) control and *GFAP-cre;Pik3ca^H1047R^* mutant hippocampus were developed using the software BioViz3D version 3.1. About 16 serial coronal sections (30 microns each) of Nissl-stained P3 control and mutant hemi-sections of forebrain were imaged and arranged in the rostro-caudal order. Contours were drawn in each section, based on morphology for the entire medial forebrain tissue and the hippocampus. The 3-D reconstruction was created using these contours from each section. The control and mutant models were marked purple and red respectively. The medial tissue for both the control and mutant were marked in a lighter shade of the afore mentioned color, to be distinguished from the darker PL. The movie was made using the movie maker software within BioViz3D and edited with VLC media player.

Verteporfin treatment {#s4-5}
---------------------

Verteporfin (20 mg/ml stock solution made in 100% mineral oil) was administered intraperitoneally at the dose of 1 μl/g of body weight, one injection per day into timed pregnant dams from E13.5 to E18.5, and the neonatal pups were harvested at P0. The number of mouse brains analyzed was 7/genotype (±verteporfin), obtained across 5 P0 litters. 100% of the mutant brains demonstrated attenuation of the gyrification and hydrocephalus phenotypes post-verteporfin treatment. For the shorter experiment, same dose of verteporfin was administered to pregnant dams from E13.5 to E16.5 and embryos were harvested at E16.5 (n = 4 brains/genotype/condition).

TUNEL staining {#s4-6}
--------------

TUNEL staining was processed on E16.5 control and mutant sections (±Verteporfin) using ApopTag Plus Fluorescein In situ Apoptosis Detection Kit.

Laser capture micro-dissection (LCM) {#s4-7}
------------------------------------

Whole forebrains were dissected from P0 (dox E13.5 \> E15.5) control and mutant mice (±verteporfin). These intact forebrains were then embedded in OCT, frozen at −80°C, and cryo-sectioned at 16 μm in the coronal plane onto PEN Membrane Glass Slides (Leica Microsystems, USA). The sections were stained with Cresyl Violet (Nissl stain). LCM was performed using the Leica LMD-6000 Laser Microdissection system to capture tissue containing the hippocampal CA1 ventricular lining of control brains and mutant hippocampal gyri and sulci, from each of the 12--14 sections mounted per slide into collection tubes. Total RNA was isolated from LCM-enriched samples pooled across \~6 slides per genotype using the Qiagen RNeasy Micro Kit and RNA quality was assessed using the Agilent Bioanalyzer 6000 Pico Kit \[RNA Integrity Number (RIN) = 7.68 ± 0.26 (mean ± s.d.)\].

RNA sequencing and analysis {#s4-8}
---------------------------

Three sequencing libraries were prepared from each RNA sample using 5 ng total RNA in the SMART-Seq v4 Ultra Low Input RNA Kit (Takara), according to the manufacturer's protocol. The cDNA was fragmented and tagged with sequencing adapters using Nextera XT kit (Illumina). The transcripts were quantified with the KAPA qPCR complete kit (BioRad) for Illumina platforms. RNA libraries were sequenced on llumina HiSeq 4000 platform. Library preparation and sequencing were performed by the Northwest Clinical Genomics Laboratory at the University of Washington. We aligned reads to the mm10 transcriptome using the salmon aligner v0.11.3 ([@bib47]), and then imported into R and summarized at the gene level using the Bioconductor tximport package, v1.8.0 ([@bib55]). We then filtered out any genes with consistently low counts (retaining those genes with \>10 counts in at least three samples). After filtering, 19,339/35,728 (54%) genes remained. Differential gene expression was performed using the Bioconductor edgeR package v3.22.3 ([@bib50]), implemented in the R programming language. We fit the model and then made comparisons using quasi-likelihood F-tests. We incorporated a log fold change \>±0.263 (representing a 20% change in expression) as part of the comparison, using the glmTreat function in edgeR ([@bib39]), and selected genes with a false discovery rate (FDR) \< 0.05. We then performed a set of self-contained gene set tests based on the PI3K pathway ([GO:0043491](http://amigo.geneontology.org/amigo/term/GO:0043491)), YAP pathway ([GO:0035329](http://amigo.geneontology.org/amigo/term/GO:0035329)), and the genes that are differentially expressed between the developing gyrus and sulcus in ferret ([@bib11]). To generate the gene set based on ferret brain, we downloaded and processed data from the Gene Expression Omnibus ([GSE60687](https://www.nbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60687)), using the Bioconductor GEOquery v2.48.0 and limma packages, v3.36.2 ([@bib10]; [@bib49]), identifying 362 genes with FDR \< 0.1. We used NCBI BLAST +to align probe sequences to the RefSeq database, then matched gene symbols to our mouse RNA-seq dataset, resulting in 168 matching genes. We generated barcode plots to help visualize results from the gene set tests using functions in the limma package. Bar graph was made in Microsoft Excel using log transformed counts, after normalizing for library size (log counts/million counts). Venn diagram was made using the online application <http://bioinformatics.psb.ugent.be/webtools/Venn/>.

Quantitative analysis {#s4-9}
---------------------

Number of mice is consistent with previous experiments completed and published by us and other investigators and based on power analyses. For histology and length measurement experiments, we performed power analyses in R using the pwr package. We used preliminary data to estimate sample variance and calculated an effect size of 1.8 between groups. We then used this effect size of 1.8 to estimate that a sample size of 5 animals per group will be required to have 80% power to detect significant differences (p=0.05) between groups. Based on this, we considered group size of 5--8 mice/genotype for each experiment to be sufficient, unless otherwise specified; extra mice/cells were considered for possible technical issues. For quantitative analysis of embryos, data was collected from comparable sections of each genotype/condition (from two or more independent litters) at each developmental stage. All measurements were made using ImageJ and ImageJ2 software programs (NIH, Bethesda, Maryland, USA). Medial tissue length was measured in the lateral ventricular lining from the dorso-medial cortical notch to the fimbrial tip ([@bib52]); the data was normalized to the control value (n = 8/genotype). P3 critical period CA1 length was measured along the mid-thickness of the PL of each mutant type; data was normalized to the P3 CA1 length (induced E0.5\>P0). Cell counts from E14.5, E16.5 and P0/P3 brains were obtained from the middle part of the CA1 dorso-ventral extent. To avoid counting discrepancies related to decreased cell density in E16.5 *Pik3ca* mutant ([@bib52]), all E16.5 cell counts were done by dividing each cell type by the total number of DAPI^+^ cells present within the fixed area of quantitation. Postnatal nYap^+^ cell distribution quantitation was done by binning the CA1 region into mono-layer apical edge, ventricular-subventricular zone (vz/svz) and the remaining area that includes the white matter (*stratum oriens*) and the pyramidal layer. Confocal stacks of immuno-stained sections of each developmental stage were generated by scanning at intervals of 0.99 μm using ﬁlters of appropriate wavelengths at 20X, 40X, 63X and 100X magnifications. Representative images for cell adhesion molecules corresponded to one 0.99μm-thick confocal plane. Measurements for labeling index (n = 7/genotype), quit fraction (n = 12/genotype), birth-dating studies (n = 5/genotype), TUNEL cell counts (n = 7 hemi-sections/genotype/condition), P0 Tbr2^+^ basal progenitor cell counts (n = 7/genotype/condition) were calculated using ImageJ. Statistical significance was assessed using 2-tailed unpaired t-tests with Welch's correction (for medial length measurements, labeling index, quit fraction and progenitor cell counts, birth-dating experiments) and ANOVA followed by Tukey post-test (one-way ANOVA for critical period CA1 length, TUNEL counts and total P3 nYap^+^ cell counts; two-way ANOVA for P0 total nYap^+^ and Tbr2^+^ cell counts, and nYap^+^ cell distribution post-verteporfin treatment). These analyses were performed in GraphPad Prism v7.0 (GraphPad Software Inc, San Diego, USA) and in Microsoft Excel. Differences were considered significant at p\<0.05. Data are represented as mean ± SEM for [Figures 2](#fig2){ref-type="fig"}, [5](#fig5){ref-type="fig"} and [7](#fig7){ref-type="fig"}, [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}. ARRIVE guidelines have been followed for reporting work involving animal research.
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RNA-seq data have been deposited in the NCBI Gene Expression Omnibus under the accession code GSE127896. Related analysed data are provided in Figure 6---source data 1 and Figure 6---source data 2 for Figure 6 and Figure 6---figure supplements 2 and 3.

The following dataset was generated:

AchiraRoyRoryM MurphyMeiDengJamesW MacDonaldTheoK BammlerKimberlyA AldingerIanA GlassKathleenJ Millen2019PI3K-Yap activity drives cortical gyrification and hydrocephalus in miceNCBI Gene Expression OmnibusGSE127896

The following previously published dataset was used:

RomeroCDBruderCMartínez-MartínezMATomaselloUSanz-AnquelaJMBorrellV2015Sharp changes in gene expression levels along germinal layers distinguish the development of gyrencephalyNCBI Gene Expression OmnibusGSE60687
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Decision letter
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Reviewing Editor

The Francis Crick Institute

United Kingdom

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"PI3K-Yap activity drives cortical gyrification and hydrocephalus in mice\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Sean Morrison as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This paper follows up on an earlier study published in *eLife* in 2015 that showed that mice with constitutive cortical expression of PI3K present cortical dysplasia and other pathological features seen in patients with intractable pediatric epilepsy. In this new paper, the authors show that the same mice present hydrocephalus and aberrant folding of the hippocampus which can be triggered by a brief activation of the pathway during embryonic development and can be attenuated by maternal delivery of the Yap inhibitor, verteporfin. They link the generation of the folds to Yap nuclear translocation and changes in apical junctions and they present the findings as evidence that regulation of apical cell adhesion of cortical progenitors underlie the initiation of cortical gyrification.

All of the reviewers find this study interesting and convincing and the experimental data of excellent quality. However there is a consensus that while this paper is framed around the idea that PIK3CA mice constitute a model of cortical gyrification, the study in fact focuses on the defects in the hippocampus, with limited analysis and illustration of the neocortical phenotype. The data presented are not sufficient to claim that the neocortical defects reflect a process of gyrification. Moreover, it is unclear whether the much more dramatic folds of the hippocampus also represent gyrification. To address these and other concerns, the reviewers request that the following essential revisions are made to the manuscript:

1\) The neocortex of PIK3CA mice should be further analysed and illustrated to provide stronger evidence of a gyrification process, or if the data are not conclusive, substantial changes should be made to the title, Abstract and text. Information on the penetrance of the phenotype and higher magnification pictures should be provided.

2\) The hippocampus of PIK3CA mice should also be further analysed and illustrated to provide more convincing evidence of a gyrification process. For example, are there differences in thickness of the putative gyri and sulci, as in a gyrated cortex?

3\) Some explanation should be provided of why the hippocampus folds much more extensively than the cortex, and why there is a posterior to anterior gradient in folding of the hippocampus. Does this reflect a gradient in PiK3CA expression levels (which should be illustrated), differences in nuclear YAP levels or in apical junction organisation, etc.?

4\) There is a discrepancy between the decrease in pHH3 expression observed in E14.5 brains and the comment (subsection "Focal increases in progenitors initiated bona fide cortical gyrification in *Pik3ca^H1047R^* mutant", second paragraph) that there is higher proliferation and expansion of apical progenitors. This should be explained or corrected.

5\) Cell death could be analysed in the hippocampus of PIK3CA mice without and with verteporfin treatment to determine whether this contributes to the phenotypes.

6\) The nuclear localisation of YAP should be better illustrated in Figure 5, particularly at E14.5 and E16.5, including with higher magnification images. The data in Figures 5 and 7 should be quantified and analysed statistically. The number of brains analysed after verteporfin treatment and the number of brains showing an attenuation of the phenotype should be provided.

7\) Hydrocephalus should be better documented. How penetrant is this phenotype? Can it be related to a structural or cellular defect in the transgenic brains (e.g. stenosis, abnormal ependymal layer)?

10.7554/eLife.45961.035

Author response

> Summary:
>
> \[...\] All of the reviewers find this study interesting and convincing and the experimental data of excellent quality. However there is a consensus that while this paper is framed around the idea that PIK3CA mice constitute a model of cortical gyrification, the study in fact focuses on the defects in the hippocampus, with limited analysis and illustration of the neocortical phenotype. The data presented are not sufficient to claim that the neocortical defects reflect a process of gyrification. Moreover, it is unclear whether the much more dramatic folds of the hippocampus also represent gyrification.

As noted below, we have added additional data and arguments demonstrating that cortical gyrification in the *Pik3ca* mutant mice is *cre*-dependent, and that both the neocortical and hippocampal tissue folding have all the hallmarks of bona fide cortical gyrification.

> To address these and other concerns, the reviewers request that the following essential revisions are made to the manuscript:
>
> 1\) The neocortex of PIK3CA mice should be further analysed and illustrated to provide stronger evidence of a gyrification process, or if the data are not conclusive, substantial changes should be made to the title, Abstract and text. Information on the penetrance of the phenotype and higher magnification pictures should be provided.

Similar to our mutant phenotype (this study; Roy et al., 2015) a study by another group using a separately generated *Pik3ca^H1047R^* mouse line under *Emx1-cre* driver, demonstrated almost identical gyrification phenotypes, in both hippocampus and neocortex (D\'Gama et al., 2017). Please refer to Figure 4 of D\'Gama et al. (2017), excerpt from the figure legend says: "...(A--D) Compared with the wild-type P7 cortex (A and C), the *Emx1-Cre;Pik3ca^H1047R^*/wt P7 cortex (B and D) is larger, with marked gyrification in the cingulate cortex, neocortex, and piriform cortex (arrows in B and D)...". This proves that the neocortical and hippocampal gyrification phenotypes are reproducible and generalizable, even across different *Pik3ca^H1047R^* transgenic mouse lines under different *cre* drivers. There was minimal analysis of the gyrification phenotype in this other paper.

In our model, there is 100% penetrance in the gyrification phenotype both in hippocampus and neocortex. The extent and positioning of folds in the neocortex are variable however. We have now provided a better characterization of the *Pik3ca* mutant neocortex, including the information on phenotypic penetrance and magnified images of the folds. See Figure 1---figure supplement 2A-J and Results and Discussion sections. Both neocortical and hippocampal folds meet all the criteria for bona fide cortical gyrification, defined in (Borrell, 2018), and this is now reiterated in the text. Point to be noted is that we have previously published that there is abnormal neuronal migration in the *hGFAP-cre;H1047R* mouse neocortex (Roy et al., 2015); hence identification of certain neocortical layers is not readily possible.

> 2\) The hippocampus of PIK3CA mice should also be further analysed and illustrated to provide more convincing evidence of a gyrification process. For example, are there differences in thickness of the putative gyri and sulci, as in a gyrated cortex?

True stereotypic cortical folding is characterized by the folding of the pial surface, the underlying neuronal layers and pial/basal side of the white matter, whereas the ventricular surface remains smooth (Borrell, 2018). We have now provided new data and illustration of the folding and of the differential thickness across *Pik3ca* mutant hippocampal gyri and sulci in Figure 1---figure supplement 2K-T.

> 3\) Some explanation should be provided of why the hippocampus folds much more extensively than the cortex, and why there is a posterior to anterior gradient in folding of the hippocampus. Does this reflect a gradient in PiK3CA expression levels (which should be illustrated), differences in nuclear YAP levels or in apical junction organisation, etc.?

We have explained this in the Results section. The *hGFAP-cre* driver used in our studies (this study; Roy et al., 2015) is active only from \~embryonic day (E)13, the time when neurogenesis in neocortex is already at its peak. Moreover, the *hGFAP-cre* line has a strong high-medial-low-lateral expression gradient. Even within the lateral neocortex, especially around E14.5 (Figure 1---figure supplement 1C, D), an apical-low-basal-high gradient is observed. Thus, we think that the time of initiation and spatio-temporal gradients of *cre* expression pattern explains the differential folding between neocortex and hippocampus.

The size of hippocampus normally is smaller in anterior coronal sections, compared to posterior sections; hence in the mutant we see more hippocampal folds in the posterior sections. We find no evidence for any gradients in YAP or apical junction organization.

> 4\) There is a discrepancy between the decrease in pHH3 expression observed in E14.5 brains and the comment (subsection "Focal increases in progenitors initiated bona fide cortical gyrification in Pik3ca^H1047R^ mutant", second paragraph) that there is higher proliferation and expansion of apical progenitors. This should be explained or corrected.

We have now corrected the E14.5 BrdU/pHH3 images since the original mutant image was not representative of the entire mutant cohort; we thank the reviewers for pointing this out. Our comment on proliferation is based on the short-pulse BrdU experiments and calculation of labeling index for each embryonic age.

> 5\) Cell death could be analysed in the hippocampus of PIK3CA mice without and with verteporfin treatment to determine whether this contributes to the phenotypes.

We have previously published that TUNEL^+^ cell number was significantly lower in E16.5 *Pik3ca^H1047R^* mutant neocortex than in control (p \< 0.01), indicating reduced apoptosis (Figure 3---figure supplement 1C in Roy et al., 2015) However the overall TUNEL^+^ cell numbers for both control and mutant were small, indicating that cortical expansion in the mutant was not primarily driven by reduced apoptosis.

We now specifically conducted the TUNEL experiment in E16.5 control and *Pik3ca* mutant (+/- verteporfin) and see no significant differences in the TUNEL^+^ cell number in the hippocampal CA1 region across groups (Figure 7---figure supplement 2H). We conclude that cell death does not contribute to the phenotypes.

> 6\) The nuclear localisation of YAP should be better illustrated in Figure 5, particularly at E14.5 and E16.5, including with higher magnification images. The data in Figures 5 and 7 should be quantified and analysed statistically. The number of brains analysed after verteporfin treatment and the number of brains showing an attenuation of the phenotype should be provided.

We have now provided images of higher magnification at E14.5 and E16.5 in Figure 5. We have also added quantification of the total number and distribution of nYap^+^ cells in the CA1 region in Figures 5 and 7. Additional details of verteporfin experiments are now further elaborated in the Materials and methods section. We used 7 mice/genotype/treatment across 5 P0 litters; 100% of the mutant brains demonstrated attenuation of the gyrification and hydrocephalus phenotypes.

> 7\) Hydrocephalus should be better documented. How penetrant is this phenotype? Can it be related to a structural or cellular defect in the transgenic brains (e.g. stenosis, abnormal ependymal layer)?

We have now clarified these points in the text. The hydrocephalus phenotype in *hGFAP-cre;Pik3ca^H1047R^*mutant mice is 100% penetrant. No stenosis has been observed in any of the mutants. Our study clearly demonstrates that defects in early ependymal development correlate with the mutant ventriculomegaly/ hydrocephalus, which in turn, was rescued by normalizing the apical ependymal/ventricular edge with verteporfin treatment.
